Renovia Inc. recently raised a total of $42 million to help facilitate its business endeavors. About $32 million of the funds came from a Series B funding. A healthcare investment company known as Longwood Fund took part in the Series B financing. Ascension Ventures and Perspective Advisors led the transaction.
As a startup headquartered in Boston, Renovia focuses on the development of diagnostics and treatments for pelvic floor ailments. The company aims at helping millions of women suffering from the disorders globally. The FDA recently approved Leva, which is Renovia’s flagship product.
Marc Beer pointed out that his company looks forward to developing better diagnostic and treatment solutions for patients with pelvic floor disorders. Beer also believes that Renovia is capable of helping the affected women understand and cope with their conditions by driving more knowledge on the ailments. He’s also confident in his company’s ability to combine state-of-the-art technologies to get resourceful data on new therapeutic options. According to him, Renovia’s inventions will help lower healthcare costs on a long-term basis.
Beer is an entrepreneur and business executive with expensive experience in pharmaceuticals, diagnostics, and biotechnology. He founded Renovia alongside Yolanda Lorié and Ramon Iglesias with a goal of helping create solutions for diverse medical conditions. Since the firm began operating in August 2016, it managed to release a couple of government approved drugs.
Renovia uses high-tech data management systems and mobile apps to create awareness on pelvic floor disorders. The company also offers value-based care and real-time assistance via smartphones and tablets to patients with the ailments. Renovia aims at focusing on futuristic innovations to deliver results and promote health. With a highly-trained leadership team, Renovia manages to design, engineer and commercialize medical solutions and treatments that can transform patients’ lives.
How Leva Works
As an FDA approved pelvic digital health system, Leva enables patients to train their pelvic floor muscles effectively. The device features motion sensor technology that can give both dynamic and static image of a woman’s reproductive profile. Patients can also use a specialized app to get coaching sessions and monitor their performance.
About Marc Beer
Marc Beer was the first chief executive of ViaCell, which collects, preserves and develops umbilical cord tissues, back in 2000. During his tenure, ViaCell successfully transitioned into a publicly traded company and managed to have over 300 individuals on its payroll. Beer was also a board member at Erytech Pharma and a Global marketing VP at Genzyme. He also worked as a diagnostic expert and marketer at Abbot Laboratories.
Before starting Renovia, Beer was a board member at Mass Life Science Board of the Commonwealth of Massachusetts. He also served as chair of Good Start Genetic’s compensation committee. He currently serves as a board member of the Miami University Business Advisory Council, Notre Dame Research and Minerva Neurosciences Inc. Learn more: https://renoviainc.com/leadership/